Drug Trial Radar · NCT05367700
A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
Last checked: Nov 19, 2026Latest source record: Jan 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
108
Planned (sponsor's estimate)
Start
Apr 28, 2022
Primary completion
Dec 30, 2024
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic(PK) profile of HS-10382 in patients with chronic myeloid leukemia (CML). Anti-CML activity will also be investigated in this study.
Conditions
- CML, Chronic Phase
- CML, Accelerated Phase
Interventions
HS-10382(Part 1: Dose escalation)Drug
Single or multiple dose(s) of HS-10382 once daily.
HS-10382(Part 2: Dose expansion)Drug
HS-10382 is administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1(Dose escalation): Maximum tolerated dose (MTD) for HS-10382Time frame: From the single dose to the last dose of the first cycle as 28days of multiple dosing (35days).
- Part 2(Dose expansion): Major cytogenetic response (MCyR) rate at 6 monthsTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.